Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease

Robert W. Hallowell, Diana Amariei, Sonye Danoff

Research output: Contribution to journalReview article

Abstract

Intravenous Ig (IVIg) is a pooled plasma product consisting primarily of monomeric IgG. For the past several decades, the use of IVIg has expanded to include the treatment of various autoimmune and inflammatory disorders, including Kawasaki's disease, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosis, and the inflammatory myopathies. IVIg is thought to exert its immunomodulatory effects through a variety of mechanisms: neutralization of pathogenic autoantibodies; alteration of immune cell effector function; suppression of cytokine and chemokine activity; and interference with complement activation. Interstitial lung disease (ILD) is a frequent complication of autoimmune disorders and connective tissue diseases, and the presence of ILD is associated with significant morbidity and mortality. Although there are currently no large studies to support the use of IVIg in the treatment of ILD, it is being used off-label with increasing frequency for refractory cases that have failed to respond to standard immunosuppression. Although associated with less systemic toxicity and global immunosuppression than traditional agents, IVIg is much more costly. Therefore, although the routine use of IVIg to treat ILD is not currently recommended, future studies to determine its role in pulmonary disease are warranted.

Original languageEnglish (US)
Pages (from-to)1682-1688
Number of pages7
JournalAnnals of the American Thoracic Society
Volume13
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Intravenous Immunoglobulins
Interstitial Lung Diseases
Immunosuppression
Systemic Vasculitis
Antineutrophil Cytoplasmic Antibodies
Mucocutaneous Lymph Node Syndrome
Myositis
Connective Tissue Diseases
Complement Activation
Therapeutics
Chemokines
Autoantibodies
Lung Diseases
Immunoglobulin G
Cytokines
Morbidity
Mortality

Keywords

  • Antisynthetase syndrome
  • Dermatomyositis
  • Interstitial lung disease
  • Intravenous Ig
  • Polymyositis

ASJC Scopus subject areas

  • Medicine(all)
  • Pulmonary and Respiratory Medicine

Cite this

Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease. / Hallowell, Robert W.; Amariei, Diana; Danoff, Sonye.

In: Annals of the American Thoracic Society, Vol. 13, No. 10, 01.10.2016, p. 1682-1688.

Research output: Contribution to journalReview article

@article{bdb46e235def447683959212793d4e79,
title = "Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease",
abstract = "Intravenous Ig (IVIg) is a pooled plasma product consisting primarily of monomeric IgG. For the past several decades, the use of IVIg has expanded to include the treatment of various autoimmune and inflammatory disorders, including Kawasaki's disease, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosis, and the inflammatory myopathies. IVIg is thought to exert its immunomodulatory effects through a variety of mechanisms: neutralization of pathogenic autoantibodies; alteration of immune cell effector function; suppression of cytokine and chemokine activity; and interference with complement activation. Interstitial lung disease (ILD) is a frequent complication of autoimmune disorders and connective tissue diseases, and the presence of ILD is associated with significant morbidity and mortality. Although there are currently no large studies to support the use of IVIg in the treatment of ILD, it is being used off-label with increasing frequency for refractory cases that have failed to respond to standard immunosuppression. Although associated with less systemic toxicity and global immunosuppression than traditional agents, IVIg is much more costly. Therefore, although the routine use of IVIg to treat ILD is not currently recommended, future studies to determine its role in pulmonary disease are warranted.",
keywords = "Antisynthetase syndrome, Dermatomyositis, Interstitial lung disease, Intravenous Ig, Polymyositis",
author = "Hallowell, {Robert W.} and Diana Amariei and Sonye Danoff",
year = "2016",
month = "10",
day = "1",
doi = "10.1513/AnnalsATS.201603-179PS",
language = "English (US)",
volume = "13",
pages = "1682--1688",
journal = "Annals of the American Thoracic Society",
issn = "2325-6621",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Intravenous immunoglobulin as potential adjunct therapy for interstitial lung disease

AU - Hallowell, Robert W.

AU - Amariei, Diana

AU - Danoff, Sonye

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Intravenous Ig (IVIg) is a pooled plasma product consisting primarily of monomeric IgG. For the past several decades, the use of IVIg has expanded to include the treatment of various autoimmune and inflammatory disorders, including Kawasaki's disease, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosis, and the inflammatory myopathies. IVIg is thought to exert its immunomodulatory effects through a variety of mechanisms: neutralization of pathogenic autoantibodies; alteration of immune cell effector function; suppression of cytokine and chemokine activity; and interference with complement activation. Interstitial lung disease (ILD) is a frequent complication of autoimmune disorders and connective tissue diseases, and the presence of ILD is associated with significant morbidity and mortality. Although there are currently no large studies to support the use of IVIg in the treatment of ILD, it is being used off-label with increasing frequency for refractory cases that have failed to respond to standard immunosuppression. Although associated with less systemic toxicity and global immunosuppression than traditional agents, IVIg is much more costly. Therefore, although the routine use of IVIg to treat ILD is not currently recommended, future studies to determine its role in pulmonary disease are warranted.

AB - Intravenous Ig (IVIg) is a pooled plasma product consisting primarily of monomeric IgG. For the past several decades, the use of IVIg has expanded to include the treatment of various autoimmune and inflammatory disorders, including Kawasaki's disease, antineutrophil cytoplasmic antibody-associated vasculitis, systemic lupus erythematosis, and the inflammatory myopathies. IVIg is thought to exert its immunomodulatory effects through a variety of mechanisms: neutralization of pathogenic autoantibodies; alteration of immune cell effector function; suppression of cytokine and chemokine activity; and interference with complement activation. Interstitial lung disease (ILD) is a frequent complication of autoimmune disorders and connective tissue diseases, and the presence of ILD is associated with significant morbidity and mortality. Although there are currently no large studies to support the use of IVIg in the treatment of ILD, it is being used off-label with increasing frequency for refractory cases that have failed to respond to standard immunosuppression. Although associated with less systemic toxicity and global immunosuppression than traditional agents, IVIg is much more costly. Therefore, although the routine use of IVIg to treat ILD is not currently recommended, future studies to determine its role in pulmonary disease are warranted.

KW - Antisynthetase syndrome

KW - Dermatomyositis

KW - Interstitial lung disease

KW - Intravenous Ig

KW - Polymyositis

UR - http://www.scopus.com/inward/record.url?scp=84992563915&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992563915&partnerID=8YFLogxK

U2 - 10.1513/AnnalsATS.201603-179PS

DO - 10.1513/AnnalsATS.201603-179PS

M3 - Review article

C2 - 27482830

AN - SCOPUS:84992563915

VL - 13

SP - 1682

EP - 1688

JO - Annals of the American Thoracic Society

JF - Annals of the American Thoracic Society

SN - 2325-6621

IS - 10

ER -